ArticleNPJ precision oncology2026
Efficacy and safety of surufatinib and sintilimab with or without chemotherapy for advanced high-grade neuroendocrine neoplasms and pancreatic cancer.
Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05627427 (Multi-cohort, Open-label, Single-centered Study of Surufatinib in Combination With Sintilimab in the Treatment of Metastatic Neuroendocrine Neoplasm and Pancreatic Carcinoma Who Failed Standard Chemotherapy), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Multi-cohort, Open-label, Single-centered Study of Surufatinib in Combination With Sintilimab in the Treatment of Metastatic Neuroendocrine Neoplasm and Pancreatic Carcinoma Who Failed Standard Chemotherapy
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroendocrine carcinoma (NEC), neuroendocrine tumor grade 3 (NET G3), and pancreatic cancer (PC) are aggressive malignancies with limited effective treatments. This study assessed the efficacy and safety of surufatinib combined with the PD-1 inhibitor sintilimab, with or without chemotherapy. In this phase II trial, 51 patients with advanced NEC (n = 30), NET G3 (n = 12), or PC (n = 9) received surufatinib plus sintilimab; the NEC cohort additionally received chemotherapy. The primary endpoint was progression-free survival (PFS). Secondary endpoints included objective response rate (ORR), disease control rate (DCR), overall survival (OS), and safety. As of August 31, 2025, the median follow-up was 18.6 months. In the NEC cohort, median PFS was 7.3 months, median OS was 13.3 months, and ORR was 53.3%. First-line NEC patients achieved superior outcomes (mPFS 7.6 months; mOS 14.3 months; ORR 65.0%) versus later-line therapy. Median PFS was 6.8 months in the NET G3 cohort and 2.1 months in the PC cohort. Adverse events were manageable; no treatment-related death occurred. Surufatinib plus sintilimab with or without chemotherapy shows encouraging efficacy and acceptable safety in advanced NEC, NET G3, and PC. This clinical trial was registered at ClinicalTrials.gov (NCT05627427) on November 15, 2022.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.